What determines the type-specific prevalence of high-risk human papillomavirus (HPV) infection?: implications for the impact of vaccination against types 16 and 18

J.A. Bogaards; J. Berkhof

What determines the type-specific prevalence of high-risk human papillomavirus (HPV) infection? implications for the impact of vaccination against types 16 and 18

J.A. Bogaards^*
, J. Berkhof

^*Corresponding author for this work

Research output: Contribution to journal › Article › Professional

Original language	English
Pages (from-to)	1-3
Number of pages	3
Journal	SACEMA Quarterly
Volume	5
Issue number	3
Publication status	Published - Sept 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{073902be711544449180f2cc487e1140,

title = "What determines the type-specific prevalence of high-risk human papillomavirus (HPV) infection?: implications for the impact of vaccination against types 16 and 18",

author = "J.A. Bogaards and J. Berkhof",

year = "2010",

month = sep,

language = "English",

volume = "5",

pages = "1--3",

journal = "SACEMA Quarterly",

number = "3",

}